Abstract
The prognosis of glioma patients is usually poor, especially in patients with glioblastoma (World Health Organization (WHO) grade IV). The regulatory functions of microRNA (miRNA) on genes have important implications in glioma cell survival. However, there are not many studies that have investigated glioma survival by integrating miRNAs and genes while also considering pathway structure. In this study, we performed sample-matched miRNA and mRNA expression profilings to systematically analyze glioma patient survival. During this analytical process, we developed pathway-based random walk to identify a glioma core miRNA-gene module, simultaneously considering pathway structure information and multi-level involvement of miRNAs and genes. The core miRNA-gene module we identified was comprised of four apparent sub-modules; all four sub-modules displayed a significant correlation with patient survival in the testing set (P-values≤0.001). Notably, one sub-module that consisted of 6 miRNAs and 26 genes also correlated with survival time in the high-grade subgroup (WHO grade III and IV), P-value = 0.0062. Furthermore, the 26-gene expression signature from this sub-module had robust predictive power in four independent, publicly available glioma datasets. Our findings suggested that the expression signatures, which were identified by integration of miRNA and gene level, were closely associated with overall survival among the glioma patients with various grades.
Highlights
Glioma is the most common form of primary brain tumor, accounting for 7% of the years of life lost from cancer before the age of 70 [1,2]
We considered the joint impact of miRNAs and genes to identify glioma survival related pathways, and developed a pathway-based random walk (PbRW) method to identify a glioma core miRNA-gene module
We developed pathwaybased random walk (PbRW) method to identify glioma core survival genes based on the glioma survival related pathways
Summary
Glioma is the most common form of primary brain tumor, accounting for 7% of the years of life lost from cancer before the age of 70 [1,2]. Despite significant improvements in treatments for glioma patients, the median survival remains poor, for those with glioblastoma (GBM, grade IV). Patients with newly diagnosed GBM exhibit a median survival of approximately one year, with generally poor responses to all therapeutic modalities [3]. A growing level of attention has been focused on the biological interplay between mRNA expression in conjunction with corresponding miRNA data in various cancer types, including glioma [5,6,7,8]. Pathway provides reliable topology structure information which could be a platform for multi-dimensional data integration. Biological pathways have been applied to explore the mechanism involved in many aspects, including disease occurrence, miRNA regulation and drug action [10,11,12]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have